Drug Discovery & Development - January 20, 2011
WESTMINSTER, Colo. (AP) - Allos Therapeutics Inc. said its lymphoma drug Folotyn helped some patients who had no response to previous therapies.
The results were based on a new analysis of a midstage clinical trial that ended in 2009, the company said late Wednesday. Out of 69 patients who had no response to their most recent treatment - meaning their tumors did not shrink at all - 17 experienced a response while they were being treated with Folotyn. The analysis also found that out of 17 patients who had no response to any previous therapy, five responded to Folotyn.
Folotyn was approved in January 2010 as a treatment for relapsed peripheral T-cell lymphoma. The company said the patients who responded to Folotyn had median survival of 14.5 months, and median survival before disease progression was 3.5 months.
The most common serious side effects of Folotyn treatment were anemia, low levels of blood platelets, lower white blood cell count, and inflammation of the mucous membranes.
The results were published in the Journal of Clinical Oncology.
Date: January 19, 2011
Source: Associated Press
The results were based on a new analysis of a midstage clinical trial that ended in 2009, the company said late Wednesday. Out of 69 patients who had no response to their most recent treatment - meaning their tumors did not shrink at all - 17 experienced a response while they were being treated with Folotyn. The analysis also found that out of 17 patients who had no response to any previous therapy, five responded to Folotyn.
Folotyn was approved in January 2010 as a treatment for relapsed peripheral T-cell lymphoma. The company said the patients who responded to Folotyn had median survival of 14.5 months, and median survival before disease progression was 3.5 months.
The most common serious side effects of Folotyn treatment were anemia, low levels of blood platelets, lower white blood cell count, and inflammation of the mucous membranes.
The results were published in the Journal of Clinical Oncology.
Date: January 19, 2011
Source: Associated Press
No hay comentarios:
Publicar un comentario